The Canadian Organization of Medical Physicists (COMP), in close partnership with the Canadian Partnership for Quality Radiotherapy (CPQR) has developed a series of Technical Quality Control (TQC) guidelines for radiation treatment equipment.
The development of the individual TQC guidelines is spearheaded by expert reviewers and involves broad stakeholder input from the medical physics and radiation oncology community. 2 All information contained in this document is intended to be used at the discretion of each individual center to help guide quality
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
and safety program improvement. There are no legal standards supporting this document; specific federal or provincial regulations and licence conditions take precedence over the content of this document.
| SYSTEM DE SCRIPTION
In recent years, stereotactic ablative radiosurgery (SABR) has moved from using rigid frames fixed to a patient's skull to the use of noninvasive frameless techniques requiring in room image guidance which are capable of treating extracranial targets. One such system is the CyberKnife â from Accuray Inc. (Sunnyvale, CA, USA) which consists of a compact linear accelerator mounted to an industrial robotic arm.
The CyberKnife â system delivers highly conformal radiation doses by delivering multiple radiation fields from many different noncoplanar directions. This is allowed for by the flexibility of the robotic arm and small size of the linac.
The central axes of these beams may share a common point of intersection (isocentric). This type of delivery provides highly conformal spherically shaped radiation dose distributions similar to those delivered using arc therapy with cones on a conventional linac. However, the vast bulk of CyberKnife â treatments use many nonisocen- 
DL2
The collimator assembly collision detector is the only mechanical interlock placed on robot motion and should be verified daily. Nonstandard patient setups and unusual treatment locations should be verified on a case-by-case basis by observing the patient plan delivery in demonstration mode.
DL3
The reference floor mark should be established when the robot is in its home position (perch) at a time when the laser indicating the beam central axes has been verified to be coincident with the radiation field center.
DL4
Prior to measuring the accelerator output, an accelerator and monitor unit chamber warm up irradiation of 6000 monitor units (MUs) for CyberKnife â models with open monitor unit chambers, and 3000 MU for sealed monitor unit chambers should be delivered.
DL5
The automated quality assurance test is a measurement similar to the Winston-Lutz test which assesses the pointing accuracy for two orthogonal beam directions using a hidden high density target and two orthogonal films. Prior to delivering this test, the x-ray system should be warmed up. The accuracy of automated robotic couch motion in response to positioning requests should also be assessed (at a minimum qualitatively) during this test.
DL6 This qualitative test is meant to verify individual leaf calibration variation and sticking through visual inspection of a series of abutted rectangular fields covering the entire range of motion as described in AAPM task group report 50. 4 Test to be performed daily or at a minimum each day the MLC is to be used for patient treatment. Quantitative analysis of these films is complicated by the lack of a flattening filter and intentional MLC defocusing used to reduce interleaf leakage on this system. For this reason, two films should be acquired for this test: one film with abutting fields (in which junctions are expected to be hot); and one film with one MLC bank offset by 0.25 mm at all junctions except for 0.5 mm at isocenter (which should have a cold junction).
The CyberKnife â radiosurgery system uses two orthogonal kilo- Notes on monthly tests ML1 Energy constancy measurements shall be made by measuring the ratio of tissue phantom ratio (TPR) or percentage depth dose (PDD) at two different depths greater than d max and separated by a minimum of 10 cm (e.g., TPR 20,10 ) using the reference field size (typically a 60 mm diameter cone or a 10 9 10 cm 2 field for systems equipped with the InCise TM MLC).
ML2 Using a dosimetry system calibrated against the local secondary standard, the output of the linac shall be checked against annual reference dosimetry.
ML3 One cranial and one extracranial end-to-end test shall be performed monthly scheduled to cycle through each clinically used tracking method, path and collimation systems (fixed, Iris TM , and InCise TM MLC). This test assesses the overall spatial targeting accuracy of the integrated CyberKnife â system for multiple beams delivered isocentrically. This test uses the relative dose delivered to two orthogonal films in a phantom geometry capable of reproducing features necessary for each tracking algorithm (e.g., moving fiducials for Synchrony â or simulated bony features for skull or spine tracking).
ML4 One cranial and one extracranial delivery quality assurance test for nonisocentric patient plans shall be performed monthly scheduled to cycle through each clinically used tracking method, path and collimation system. This test assesses the dosimetric accuracy of the entire system for nonisocentric delivery. An appropriate detector shall be used for the field sizes and dose gradients within the plan to be measured. For example, for plans using small collimators (≤10 mm in diameter), the use of radiochromic film is strongly recommended. Action levels for these tests refer to >90% pass rate for pixels in the high dose region (>50% isodose) for a gamma metric with the stated absolute dose percent difference/distance-to-agreement criteria.
ML5 This test verifies the field size long-term stability and reproducibility of the Iris TM variable collimator by comparing to a baseline set of measurements immediately following beam data collection. Radiochromic film or equivalently high spatial resolution detector should be used. A smaller subset of field sizes may be tested each month provided that, at a minimum, all clinically used field sizes are rotating through quarterly.
ML6 For systems equipped with the InCise TM MLC, the "Garden fence" MLC test 5 shall be performed monthly to provide quantitative information about MLC calibration for individual leaves.
ML7 Images of a phantom intended for planar kV image quality shall be acquired monthly and compared to a baseline. Ensure that an x ray warm-up has been performed prior to image acquisition. The phantom's low and high contrast structures should be oriented perpendicular to the imaging systems' central axes (i.e., in a stand rotated 45 degrees with respect to the horizontal direction). At a minimum, lowcontrast visibility and high-contrast spatial resolution features should be assessed qualitatively (e.g., maximum number of low-contrast objects visible, maximum number of line pairs/mm visible) and compared to the baseline.
ML8 Documentation relating to the daily quality control checks, preventive maintenance, service calls, and subsequent return to service must be complete, legible, and the operator identified.
VANDERVOORT ET AL. Notes on quarterly tests
QL1-2
The beam shape and beam symmetry should be compared to values obtained during commissioning, typically using the 60 mm diameter collimator and a high resolution detector such as radiochromic film. If film is used, agreement with commissioning data refers to a >90% pass rate for a gamma metric with the stated absolute dose percent difference/distance-to-agreement criteria. Alternatively, if a detector array is used, it is recommended that at least three radial locations across 80% of the nominal field width are evaluated for this check with action and tolerance levels based on the stated percent differences from a baseline acquired using the same device immediately following beam data collection.
QL3
The alignment of the imaging system with respect to the isocrystal shall be assessed by acquiring images of the isopost and measuring the distance between the centroid of the crystal and center of the imager field of view for each imaging panel. annually. Systems not equipped with the InCise TM MLC are not capable of producing a 10 9 10 cm 2 field and therefore beam quality metrics necessary to determine k Q for the fictitious reference field must be estimated using 60 mm cone data with equivalent field size corrections and standard reference data such as BJR supplement 25. A secondary independent check using optically stimulated luminescent dosimeters (OSLD) or thermoluminescent dosimeters (TLD) program through an accredited dosimetry calibration lab (ADCL) is also recommended.
AL2
Beam data checks of TPR (or PDD) and output factors for at least three field sizes for each clinically used collimator system in clinical use including the largest and smallest field size used. Care should be taken to use the same detector as that used during commissioning; particularly PDD data and output factors are especially sensitive to detector design for small fields.
AL3
Radial profile measurements should be made for at least three field sizes for each clinically used collimator system in clinical use including the largest and smallest field size used.
AL4
Dose output linearity and end monitor effect are verified annually including the lowest MU beam permitted clinically (typically 5 MU although the planning system allows 1 or 2 MU).
AL5
Coincidence of the central axis beam laser and radiation central axis should be better than 1 mm (action level) and should not have changed from the baseline by more than 0.5 mm (tolerance level). Measurements at two different distances from the radiation source (e.g., in the birdcage assembly and on the floor) are recommended assessing orthogonality of the laser. This test should also be performed before any verification or recalibration of the first-and second-order path calibrations.
AL6
Verification of the second-order path calibration for all clinically used pathsets shall be performed annually. If this test is performed as part of the preventative maintenance or during a path calibration, the verification reports will be reviewed by a medical physicist as part of annual quality control. In the current version of the software (CyberKnife â System V10.X or less), this is only possible in the service mode with the help of an experienced service engineer.
AL7
A Synchrony â end-to-end test run with at least a 20°phase shift between the LED markers and internal motion provides a measure of the system's ability to correct for a lag between internal and external motion. The 20°phase shift can easily be achieved via setting on the vendor supplied Synchrony â quality assurance tool motion phantom.
AL8-11
The leakage, transmission characteristics of the InCise TM MLC shall be compared to baseline values determined at the time of commissioning as well as assessment of the alignment of MLC leaves. 
AL12
Test methods for kVp, mA, and timer accuracy, exposure linearity, and reproducibility shall be performed annually and following any significant change to the kV imaging system done during preventative maintenance or machine service. These data should be acquired by firing the x-ray tubes one at a time (currently not possible through the CyberKnife â console standard interface) using a range of imaging parameters for both focal spot sizes. Ensure that an x-ray warm-up has been performed prior to image acquisition. Procedure development may require the assistance of a field service engineer.
AL13
A more quantitative version of the monthly image quality test shall be performed annually and following any significant service to the kV imaging system. Ensure that an x-ray warm-up has been performed prior to image acquisition. Raw or processed images from each panel may be extracted from the system using the treatment fraction download (TFDL) utility on the treatment console computer using a terminal emulator and ssh-based file transfer program (e.g., PuTTY).
AL14
To ensure redundancy and adequate monitoring, a second qualified medical physicist must independently verify the implementation, analysis, and interpretation of the quality control tests at least annually. Quality assurance references should be updated annually as needed including acquiring new CT scans and plans for phantoms used in end-to-end testing.
